MedTrace Logo

Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer

NCT00754351 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2012-06-28

No results posted yet for this study

Summary

This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab combination, administered biweekly, as salvage treatment in patients with metastatic and HER2 negative breast cancer.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression

DRUG

Docetaxel

Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles

DRUG

Gemcitabine

Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles

Sponsors & Collaborators

  • University Hospital of Crete

    lead OTHER

Principal Investigators

  • Dimitris Mavrudis, MD · University Hospital of Crete, Dep of Medical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00754351 on ClinicalTrials.gov